Company Overview
Snapshot
Founded in January 2024 by Gary Schonberg, Predose operates with 1–10 employees. The company is currently in a Pre-Funding stage, focusing on developing its automated platform for precision drug dosing. In January 2025, Predose was recognized as one of nine Israeli startups selected to help improve healthcare in the UK.
Business overview
Predose is developing an automated platform that leverages patient-specific data and cloud-based technology to customize individual drug-dosing regimens directly at the clinic. The software integrates drug-specific clinical knowledge into mechanistic models, utilizes patient-specific covariates to create personalized "virtual twins," and automates the end-to-end precision dosing workflow. The company aims to improve patient outcomes and transform clinical pharmacology, serving the health tech and life sciences sectors, specifically within digital healthcare and medical decision support.
Strategic signal
In January 2025, Predose was highlighted as one of nine Israeli startups selected to contribute to improving healthcare in the UK. This recognition signals strong international validation for Predose's innovative approach to precision dosing and indicates potential for market expansion and strategic partnerships within the European healthcare landscape.
Log in to access full profile ›Company Intelligence Q&A
- When was Predose founded?
- Predose was founded in January 2024.
- Who is the founder of Predose?
- Gary Schonberg is the founder of Predose.
- What is Predose's primary focus?
- Predose is developing an automated platform for precision drug dosing, leveraging patient-specific data and cloud-based technology to customize individual drug-dosing regimens at the clinic.
- What is the employee size of Predose?
- Predose currently has 1–10 employees.
- What significant recognition did Predose receive in early 2025?
- In January 2025, Predose was identified as one of nine Israeli startups selected to contribute to improving the UK's healthcare system.